Analyst Jason McCarthy of Maxim Group maintained a Buy rating on SCYNEXIS, retaining the price target of $4.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy has given his Buy rating due to a combination of factors, primarily focusing on SCYNEXIS’s strategic developments and financial health. The company reported a significant increase in revenue, attributed to its licensing agreement with GSK, and maintains a solid cash position, which is expected to support its operations into late 2026. This financial stability is crucial as SCYNEXIS continues to advance its clinical programs.
Furthermore, the ongoing progress in the MARIO study and the anticipated relaunch of Brexafemme through GSK are pivotal. The potential resolution of milestone payment disputes with GSK could further enhance SCYNEXIS’s financial position. Additionally, the promising development of SCY-247, a next-generation antifungal candidate, with its expected Phase 1 data in the third quarter of 2025, underscores the company’s innovative pipeline. These factors collectively contribute to McCarthy’s optimistic outlook on SCYNEXIS’s stock.
SCYX’s price has also changed moderately for the past six months – from $1.120 to $0.801, which is a -28.48% drop .